Evaluate Immunogenicity, Safety and Reactogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-Dose Primary Immunization in Children Before 6 mo of Age

Trial Profile

Evaluate Immunogenicity, Safety and Reactogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-Dose Primary Immunization in Children Before 6 mo of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine
  • Indications Otitis media; Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Aug 2010 Additional location identified [Czech Republic] as reported by ClinicalTrials.gov.
    • 09 Jul 2008 Actual patient number (600) added as reported by ClinicalTrials.gov.
    • 09 Jul 2008 GlaxoSmithKline Biologicals reported as trial affiliate by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top